Inclusion Criteria:

- Histologically documented classical Hodgkin lymphoma that is recurrent or refractory
to standard chemotherapy.

- Patients must have relapsed or progressed after at least one prior systemic cytotoxic
chemotherapy; prior autologous or allogeneic stem cell transplantation is allowed.

- Measurable disease must be present either on physical examination or imaging studies
(CT, MRI, PET/CT). Any tumor mass greater or equal to 1 cm is acceptable.

- Age > 18 years old.

- ECOG performance status of less than or equal to 2 at study entry (see Appendix 1).

- Adequate hematologic, renal, hepatic function as defined by:

- Absolute neutrophil count greater than or equal to 1000 / uL

- Platelets greater than or equal to 50,000 / uL

- Serum creatinine less than or equal to 1.5X institution upper limit of normal
(ULN)

- Total bilirubin less than or equal to 2.0 mg/dL

- AST (SGOT) and ALT (SGPT) less than or equal to 3 x ULN (if not attributed to
cHL)

- Disease free of prior malignancies for greater than or equal to 5 years with
exception of currently treated basal cell, squamous cell carcinoma of the skin, or
carcinoma "in situ" of the cervix or breast.

- Understand and voluntarily sign an informed consent form.

- Able to adhere to the study visit schedule and other protocol requirements

- Females of childbearing potential (FCBP)† must agree to use two reliable forms of
contraception simultaneously or to practice complete abstinence from heterosexual
intercourse during the following time periods related to this study: 1) for at least
28 days before starting study drug; 2) while participating in the study; and 3) for
at least 28 days after discontinuation from the study. The two methods of reliable
contraception must include one highly effective method (i.e. intrauterine device
(IUD), hormonal [birth control pills, injections, or implants], tubal ligation,
partner's vasectomy) and one additional effective (barrier) method (i.e. latex
condom, diaphragm, cervical cap). FCBP must be referred to a qualified provider of
contraceptive methods if needed.

- FCBP must have two negative serum or urine pregnancy tests (sensitivity of at least
50 mIU/mL) prior to starting study drug. The first pregnancy test must be performed
within 10-14 days prior to the start of study drug and the second pregnancy test must
be performed within 24 hours prior to prescribing lenalidomide for Cycle 1
(prescriptions must be filled within 7 days as required by RevAssist) and must either
commit to continued abstinence from heterosexual intercourse or begin TWO acceptable
methods of birth control, one highly effective method and one additional effective
method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. The
subject may not receive study drug until the Investigator has verified that the
results of these pregnancy tests are negative. - Men must agree to use a latex
condom during sexual contact with females of childbearing potential while
participating in the study and for at least 28 days following discontinuation from
the study even if he has undergone a successful vasectomy.

- All patients must be counseled at a minimum of every 28 days about pregnancy
precautions and risks of fetal exposure.

- Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients
intolerant to ASA may use warfarin or low molecular weight

- All study participants must be registered into the mandatory RevAssist program, and
be willing and able to comply with the requirements of RevAssist.

Exclusion Criteria:

- Patients who are candidates for high dose chemotherapy and stem cell transplantation
and have not yet undergone stem cell transplantation should not be enrolled.

- Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from signing the informed consent form.

- Any condition, including the presence of laboratory abnormalities.

- Use of any other anti-cancer drug or therapy, including experimental, within 30 days
of enrollment.

- Known hypersensitivity to thalidomide.

- The development of erythema nodosum if characterized by a desquamating rash while
taking thalidomide or similar drugs.

- Any prior use of lenalidomide.

- Known positive for HIV or infectious hepatitis, type A, B or C.

- Pregnant or breastfeeding females.

- Concurrent use of other anti-cancer agents or treatments.